Posted by Michael Wonder on 26 Nov 2020
Takhzyro is not included in the high-cost protection
26 November 2020 - Takhzyro (lanadelumab) is a subcutaneous injection intended for routine prevention of recurrent hereditary seizures, angioedema in patients aged twelve years and older.
The company has analyzed a limited group within Takhzyro's approved indication. This group includes patients with severe illness and many seizures. For these patients, the severity of the disease is judged to be high. In the health economic analyzes, preventive treatment with Takhzyro is compared with only acute treatment in connection with a seizure.
